Disclosed herein is a device configured to impart flavoring to an airstream admitted the device prior to the airstream reaching an aerosol generator of the device, the device thereby operable to deliver a flavored aerosol from an outlet.

A nasal seal, mask or an interface assembly have a seal body defining a breathing chamber. A nasal port is provided in the seal body. The nasal port has a central portion straddled by a pair of lateral portions. The nasal port further has an upper edge and a lower edge. The upper edge defines an inwardly projecting portion within the central portion. The lower edge defines an inwardly protection portion within the central portion. Thus, the nasal port can be generally bean-shaped or bowtie-shaped. The mask can include a frame having a central portion that supports the seal and a pair of arm portions that extend rearwardly of the seal and are configured to connect to headgear. The central portion can be more rigid than the arm portions. The mask can be configured to reduce noise transmitted through a bias flow vent.

An access system has a scanner that scans a unique identifier to access a location. A display receives an input. An automated dispenser dispenses at least one scent on each hand of an individual responsive to a control signal. A processor controls access to the location. A memory stores a set of instructions that configures the processor to receive the unique identifier from the scanner, actuate the automated dispenser to dispense the at least one scent responsive to receipt of the unique identifier, receive the response input based on the scents detected by the individual of the at least one scent, determine a passing result or a failing result responsive to the received response input and an expected response based on the dispensed at least one scent, enable access to the location responsive to a passing result and deny access to the controlled access location responsive to a failing result.

An indicating device includes a mechanical dose counter adapted to count the number of doses that have been dispensed from or remain in a container and an electronic module coupled to the mechanical dose counter and adapted to record when the doses have been dispensed from the container. Methods of using and assembling the device are also provided.

Scent infused nasal cannulas, scent infused nasal cannula assemblies, methods of providing scents to subjects, and methods of fabricating scent infused nasal cannulas. The scent infused nasal cannulas and scent infused nasal cannula assemblies include a tubular body, a pair of narine projections, and fluid supply tubes. The tubular body and the pair of narine projections are formed from a scent infused polymer. The methods of providing scents to subjects include attaching a scent infused nasal cannula to a subject and delivering a fluid from a fluid source to the subject during the emission period of the scent infused polymer such that the scent is detectable therefrom. The methods of fabricating scent infused nasal cannulas include providing a scent infused nose piece and attaching fluid supply tubes to the nose piece and to a fluid source.

A nasal seal, mask or an interface assembly have a seal body defining a breathing chamber. A nasal port is provided in the seal body. The nasal port has a central portion straddled by a pair of lateral portions. The nasal port further has an upper edge and a lower edge. The upper edge defines an inwardly projecting portion within the central portion. The lower edge defines an inwardly protection portion within the central portion. Thus, the nasal port can be generally bean-shaped or bowtie-shaped. The mask can include a frame having a central portion that supports the seal and a pair of arm portions that extend rearwardly of the seal and are configured to connect to headgear. The central portion can be more rigid than the arm portions. The mask can be configured to reduce noise transmitted through a bias flow vent.

A patient interface includes a sealing arrangement adapted to provide an effective seal with the patient's nose, an inlet conduit arrangement adapted to deliver breathable gas to the sealing arrangement, and a cover that substantially encloses the sealing arrangement and/or the inlet conduit arrangement.

Disclosed are novel compositions, devices, patches, systems and methods that are useful for estimating, determining, modulating and/or improving the sleep/wake and/or circadian phase of a subject (e.g., a human subject) by the dispensing of measured quantities of agents to a subject or into an environment of the subject and the continuous monitoring and/or tracking of the subject's consciousness (e.g., sleep/wake) patterns. In certain aspects, the compositions, devices, patches, systems and methods disclosed herein are capable of delivering one or more agents to a subject in response to measured consciousness patterns estimations and circadian phase estimations, thereby aligning the subject's circadian biology to the external environment and improving the quality and duration of sleep.

An air delivery system for providing a supply of air from a source of air at positive pressure to an interfacing structure located at the entrance to the airways of a patient includes a manifold adapted to connect with the supply of positive air pressure and at least one tube connected to the manifold and adapted to deliver the supply of air to the interfacing structure. Each tube is structured to allow movement between an open phase in which the tube allows the passage of air and a collapsed phase in which the tube is collapsed. Each tube is structured such that weight of a typical patient's head against bedding apparel is sufficient to collapse the tube from the open phase to the collapsed phase.

Combinatorial therapeutic systems can include an artificial sensory experience and a therapeutically effective amount of an analgesic selected from tapentadol or difelikefalin (CR845). Methods for treating and/or mitigating pain can include at least (i) receiving a therapeutic dose of an analgesic selected from tapentadol or difelikefalin (CR845) and (ii) receiving an artificial sensory experience. The artificial sensory experience can include one or more of 2D/3D/4D artificial sensory experiences, holography, augmented reality, virtual reality, and/or mixed reality. In some instances, the artificial sensory experience is virtual reality neuropsychological therapy or virtual reality distraction therapy.